

20 August 2007

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
(NICE)
Peter House
Oxford Road
Manchester
M1 5AN



Llywodraeth Cynulliad Cymru
Welsh Assembly Government

Dear Carole

Single Technology Appraisal – Velcade (bortezomib) for multiple myeloma

Further to recent the correspondence between NICE and the Department of Health, I can confirm that the proposed adjustments to the Velcade responder scheme in terms of responder definition are also acceptable to the Welsh Assembly Government.

Yours sincerely



Quality, Standards and Safety Improvement Directorate

